Zydus Cadila has received the final approval from the USFDA to market Amiloride Hydrochloride Tablets USP, 5 mg. The drug falls in the diuretics segment. The group now has 101 approvals and has so far filed over 260 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.
